A Phase 1 interventional study of Embibatinib and Rabeprazole in Healthy, sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time. Researchers will compare what happens to different doses and forms of Embibatinib in a person's body over time when given with or without food, or with or without other medications.
The goal of the study is to learn:
Per protocol, participants will be randomized in Cohort 7 to the sequence in which they receive two Embibatinib formulations. All other cohorts will be non-randomized.
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
First submitted after Terns, Inc. became part of Merck & Co., Inc.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 22, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral dose of Embibatinib Dose Level 1 under fasted conditions on Day 1.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib Dose Level 2 under fasted conditions on Day 1.
Drug: Embibatinib
On Period 1 Day 1, participants receive a single oral dose of Embibatinib Dose Level 3 under fasted conditions. On Period 2 Day 1, participants receive Embibatinib Dose Level 3 after a high-fat meal.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib Dose Level 4 under fasted conditions on Day 1.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib Dose Level 5 under fasted conditions on Day 1.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib Dose Level 7 under fasted conditions on Day 1.
Drug: Embibatinib
Participants in Cohort 7 are randomized to receive Embibatinib Formulation 1 or Formulation 2 at Dose Level 5 on Day 1. On Day 7, participants receive Embibatinib Formulation 2 or Formulation 1 at Dose Level 5. Participants also receive Rabeprazole 20 mg once daily on Days 10-13. On Day 14, participants will co-administer a single oral dose of Rabeprazole 20 mg with Embibatinib Formulation 1 Dose Level 5 at the same time. All participants receive treatment under fasted conditions.
Drug: Embibatinib · Drug: Rabeprazole
Per protocol, the probe substrate cocktail-1 consists of midazolam 2 mg, digoxin 0.25 mg, pravastatin 40 mg, montelukast 10 mg, and omeprazole 40 mg. On Day 1, participants receive a single oral dose of the probe substrate cocktail-1 under fasted conditions. On Day 5, participants receive a single oral dose of Embibatinib Dose Level 4 co-administered with a single oral dose of the probe substrate cocktail-1 taken at the same time under fasted conditions. On Day 9, participants receive a single oral dose of Embibatinib Dose Level 7 co-administered with a single oral dose of the probe substrate cocktail-1 taken at the same time under fasted conditions.
Drug: Embibatinib · Drug: Midazolam · Drug: Digoxin · Drug: Pravastatin · Drug: Montelukast · Drug: Omeprazole
Participants receive a single oral dose of Embibatinib Dose Level 5 on Day 1 under fasted conditions. On Days 4-7 participants will receive Rabeprazole 20 mg once daily under fasted conditions. On Day 8, under fasted conditions, participants co-administer a single oral dose of Embibatinib Dose Level 5 with a single oral dose of Rabeprazole 20 mg taken at the same time under fasted conditions.
Drug: Embibatinib · Drug: Rabeprazole
Participants receive a single oral dose of Embibatinib Dose Level 8 under fasted conditions on Day 1.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib Dose Level 9 under fasted conditions on Day 1.
Drug: Embibatinib
Participants receive a single oral dose of Embibatinib at Dose Level 3 under nonfasted conditions on Day 1. On Day 8, participants will receive Itraconazole 200 mg twice daily after a standardized breakfast and evening snack. On Days 9-11, participants will take a single oral dose of Itraconazole 200 mg after a standardized meal. On Day 12, participants will take a single dose of Itraconazole 200mg after a standardized meal followed by Embibatinib Dose Level 3 taken an hour later. Participants will continue taking a single oral dose of Itraconazole 200 mg once daily after a standardized meal on Days 13-15.
Drug: Embibatinib · Drug: Itraconazole
Participants receive an oral dose of Embibatinib Dose Level 4 once daily from Day 1 to Day 13 under fasted conditions.
Drug: Embibatinib
Per protocol, the probe substrate cocktail-2 consists of midazolam 2 mg, warfarin 5 mg, and rosuvastatin 10 mg. Participants receive a single oral dose of the Probe Substrate Cocktail-2 on Day 1 under fasted conditions. On Days 9-15, participants receive a single oral dose of Embibatinib Dose Level 5 once daily under fasted conditions. On Day 16, participants receive a single oral dose of the Probe Substrate Cocktail-2 co-administered with Embibatinib Dose Level 5 taken at the same time under fasted conditions. On Days 17-21 participants receive Embibatinib Dose Level 5 as a single oral dose once daily under fasted conditions.
Drug: Embibatinib · Drug: Midazolam · Drug: Warfarin · Drug: Rosuvastatin
Per protocol, the probe substrate cocktail-2 consists of midazolam 2 mg, warfarin 5 mg, and rosuvastatin 10 mg. Participants receive a single oral dose of the Probe Substrate Cocktail-2 on Day 1 under fasted conditions. On Days 9-15, participants receive a single oral dose of Embibatinib Dose Level 8 once daily under fasted conditions. On Day 16, participants receive a single oral dose of the Probe Substrate Cocktail-2 co-administered with Embibatinib Dose Level 8 taken at the same time under fasted conditions. On Days 17-21 participants receive Embibatinib Dose Level 8 as a single oral dose once daily under fasted conditions.
Drug: Embibatinib · Drug: Midazolam · Drug: Warfarin · Drug: Rosuvastatin
On Period 1 Day 1, participants receive a single oral dose of Embibatinib Formulation 3 Dose Level 8 (DL8). On Period 1 Day 7, participants receive a single oral dose of Embibatinib Formulation 4 DL8. On Period 1 Day 13, participants receive a single oral dose of Embibatinib Formulation 5 DL8. On Period 1 Day 19, participants receive a single oral dose of Embibatinib Formulation 6 DL8. All Period 1 treatments are administered under fasted conditions. Per protocol, following Period 1, one formulation is selected for Period 2. On Period 2 Day 1, participants receive a single oral dose of the selected Embibatinib formulation DL8 after a high-fat meal. On Period 2 Days 7-10, participants receive rabeprazole 20 mg once daily under fasted conditions. On Period 2 Day 11, participants receive the selected formulation of Embibatinib DL8 as a single oral dose, co-administered with the single oral dose of Rabeprazole 20 mg taken at the same time under fasted conditions.
Drug: Embibatinib · Drug: Rabeprazole
Per protocol, a formulation from Cohort 16 Period 1, different from the formulation selected for Cohort 16 Period 2, may be selected to evaluate the effects of food and rabeprazole 20 mg. On Day 1, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 under fasted conditions. On Day 7, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 after a high-fat meal. On Days 13-16, participants receive a single oral dose of rabeprazole 20 mg once daily. On Day 17, participants receive a single oral dose of the selected formulation of Embibatinib Dose Level 8 co-administered with a single oral dose of rabeprazole 20 mg taken at the same time under fasted conditions.
Drug: Embibatinib · Drug: Rabeprazole
On Day 1, participants receive a single oral dose of Embibatinib Dose Level 8 under fasted conditions. Beginning on Day 8, participants receive an oral dose of Bosentan 125 mg twice daily. On Day 15, participants receive Embibatinib Dose Level 8 as a single oral dose co-administered with the morning dose of Bosentan 125 mg taken at the same time under fasted conditions; participants then receive the second daily dose of Bosentan 125 mg in the evening. Participants continue taking Bosentan 125 mg twice daily on Days 16-18.
Drug: Embibatinib · Drug: Bosentan
Participants receive a single oral dose of Embibatinib Dose Level 6 on Day 1 under fasted conditions. Beginning on Day 6, participants receive an oral dose of Quinidine 300 mg three times daily. On Day 8, participants receive Embibatinib Dose Level 6 as a single oral dose co-administered with the morning final dose of Quinidine 300 mg taken at the same time under fasted conditions.
Drug: Embibatinib · Drug: Quinidine
Oral Tablet
Also known as: MK-4208, HS-10382
The United States commercially marketed 20 mg oral tablet formulation is being used in this trial.
2 mg oral syrup formulation administered as part of the probe substrate cocktail-1 and probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
0.25 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
10 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
40 mg oral tablet formulation administered as part of the probe substrate cocktail-1. The United States commercially marketed formulation is being used in this trial.
The United States commercially marketed 200 mg oral capsule formulation is being used in this trial.
5 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
10 mg oral tablet formulation administered as part of the probe substrate cocktail-2. The United States commercially marketed formulation is being used in this trial.
The Europe commercially marketed 125 mg oral tablet formulation is being used in this trial.
The United States commercially marketed 300 mg oral tablet formulation is being used in this trial.
Number of Participants Who Experience a Treatment Emergent Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a treatment emergent AE will be reported.
Time frame: Up to approximately 102 days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 102 days
Number of Participants with Clinically Significant Abnormalities in Systolic Blood Pressure
Blood pressure will be measured after the participant has been at rest in a supine position for at least 10 minutes. Blood pressure and pulse measurements will be assessed with a completely automated device; manual techniques will be used only if an automated device is not available. Blood pressure measurements will be carried out before blood sample collections or at least 30 minutes after any blood draws.
Time frame: up to approximately 102 days
Number of Participants with Clinically Significant Abnormalities in Diastolic Blood Pressure
Blood pressure will be measured after the participant has been at rest in a supine position for at least 10 minutes. Blood pressure and pulse measurements will be assessed with a completely automated device; manual techniques will be used only if an automated device is not available. Blood pressure measurements will be carried out before blood sample collections or at least 30 minutes after any blood draws.
Time frame: up to approximately 102 days
Number of Participants with Abnormal Clinical Hematology Test Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal hematology-related AEs will be reported.
Time frame: up to approximately 102 days
Number of Participants with Abnormal Clinical Chemistry Test Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal chemistry-related AEs will be reported.
Time frame: up to approximately 102 days
Number of Participants with Abnormal Urinalysis Results Reported as Adverse Events
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with abnormal urinalysis-related AEs will be reported.
Time frame: up to approximately 102 days
Number of Participants with Clinically Significant Abnormalities in 12-Lead (ECG) Findings
During the 12-lead ECG collection participants will be instructed to lie supine for at least 10 minutes prior to ECG collection. During the collection, participants should be in a quiet setting, without distractions, and should refrain from talking or moving their arms or legs. All ECG acquisitions will be carried out before any blood sample collections or at least 30 minutes after any blood draws.
Time frame: up to approximately 102 days
Area Under the Concentration versus Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of Embibatinib in Plasma
Blood samples will be collected to determine the AUC0-Last of Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Area Under the Concentration versus Time Curve Extrapolated to Infinite Time (AUC0-Inf) of Embibatinib in Plasma
Blood samples will be collected to determine the AUC0-inf of Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Area Under the Concentration versus Time Curve Over the Dosing Interval (AUCtau) of Embibatinib in Plasma
Blood samples will be collected to determine the AUCtau of Embibatinib.
Time frame: Pre-dose and at designated time points up to 24 hours post dose
Maximum Observed Concentration of Drug (Cmax) of Embibatinib in Plasma
Blood samples will be collected to determine the Cmax of Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Apparent Terminal Elimination Half-Life (t1/2) of Embibatinib in Plasma
Blood samples will be collected to determine the t1/2 of Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Time of Maximum Observed Concentration of Drug (Tmax) of Embibatinib in Plasma
Blood samples will be collected to determine the Tmax of Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib in Plasma Under Fed Versus Fasted Conditions
Blood samples will be collected to determine the AUC0-Last of Embibatinib under fed versus fasted conditions.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib in Plasma Under Fed Versus Fasted Conditions
Blood samples will be collected to determine the AUC0-inf of Embibatinib under fed versus fasted conditions.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib in Plasma Under Fed Versus Fasted Conditions
Blood samples will be collected to determine the Cmax of Embibatinib under fed versus fasted conditions.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Tmax of Embibatinib in Plasma Under Fed Versus Fasted Conditions
Blood samples will be collected to determine the Tmax of Embibatinib under fed versus fasted conditions.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib Formulations in Plasma
Blood samples will be collected to determine the AUC0-Last of Embibatinib formulations.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib Formulations in Plasma
Blood samples will be collected to determine the AUC0-Inf of Embibatinib formulations.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib Formulations in Plasma
Blood samples will be collected to determine the Cmax of Embibatinib formulations.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent
Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without an acid-reducing agent.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent
Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without an acid-reducing agent.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib in Plasma Administered With or Without an Acid-Reducing Agent
Blood samples will be collected to determine the Cmax of Embibatinib administered with or without an acid-reducing agent.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Midazolam in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Midazolam administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Midazolam in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Midazolam administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Midazolam in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Midazolam administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Montelukast in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Montelukast administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Montelukast in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Montelukast administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Montelukast in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Montelukast administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Omeprazole in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Omeprazole administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Omeprazole in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Omeprazole administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Omeprazole in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Omeprazole administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Digoxin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Digoxin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Digoxin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Digoxin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Digoxin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Digoxin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Pravastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Pravastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Pravastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Pravastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Pravastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Pravastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Warfarin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Warfarin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Warfarin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Warfarin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Warfarin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Warfarin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Rosuvastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-Last of Rosuvastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Rosuvastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the AUC0-inf of Rosuvastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Rosuvastatin in Plasma Administered With or Without Embibatinib
Blood samples will be collected to determine the Cmax of Rosuvastatin administered with or without Embibatinib.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib in Plasma Administered With or Without Itraconazole
Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without itraconazole.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib in Plasma Administered With or Without Itraconazole
Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without itraconazole.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib in Plasma Administered With or Without Itraconazole
Blood samples will be collected to determine the Cmax of Embibatinib administered with or without itraconazole.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib in Plasma Administered With or Without Bosentan
Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without Bosentan.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib in Plasma Administered With or Without Bosentan
Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without Bosentan.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib in Plasma Administered With or Without Bosentan
Blood samples will be collected to determine the Cmax of Embibatinib administered with or without Bosentan.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-last of Embibatinib in Plasma Administered With or Without Quinidine
Blood samples will be collected to determine the AUC0-Last of Embibatinib administered with or without Quinidine.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
AUC0-Inf of Embibatinib in Plasma Administered With or Without Quinidine
Blood samples will be collected to determine the AUC0-inf of Embibatinib administered with or without Quinidine.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Cmax of Embibatinib in Plasma Administered With or Without Quinidine
Blood samples will be collected to determine the Cmax of Embibatinib administered with or without Quinidine.
Time frame: Pre-dose and at designated time points up to 96 hours post dose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2023 to primary completion in Jun 2026, 30 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Embibatinib
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) →